ST. LOUIS (KMOX) - A Swedish-based medical device company is set to move their U.S. headquarters to St. Louis.
Senzime, in a press release back on Jan. 17, announced plans to move their U.S. headquarters from Boston to St. Louis, with headquarters to be located in Brentwood.
The company cites the move due to increased market demands for Senzime’s products and solutions, which included the company securing several major hospital contract in 2023.
"The relocation of our US headquarters to scalable offices in St. Louis enables more rapid, cost-effective, and sustainable shipments to hospitals across the US. We have strong financial backing, but reduced overhead expenses actually makes this US commercial expansion cost-neutral," said Philip Siberg, CEO of Senzime.
Senzime is a Swedish medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems, including systems like the company's TetraGraph system, a quantitative neuromuscular monitoring system used by anesthesiologists at hundreds of leading hospitals across the globe to help improve patient safety during and after surgery.
The move will mark a return to St. Louis for Siberg, who has previous ties to the area. Before becoming CEO of Senzine, he was the CEO and Co-founder of Coala Life, a company similar to Senzine. Coala Life participated in the 2019 Innovation Summit hosted by Global STL and originally had plans to settle in St. Louis, but they ultimately moved to California.
Senzine has seeing massive business growth last year in 2023, with the company reported a 163% rise in net sales for the first nine months of 2023.